2023
Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy
Cartwright E, Pierret C, Minassian C, Esserman D, Tate J, Goetz M, Bhattacharya D, Fiellin D, Justice A, Re V, Rentsch C. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy. JAMA Network Open 2023, 6: e2335715. PMID: 37751206, PMCID: PMC10523171, DOI: 10.1001/jamanetworkopen.2023.35715.Peer-Reviewed Original ResearchConceptsSustained virologic responseAlcohol use disorderHigh-risk consumptionHistory of AUDLow-risk consumptionDAA therapyAlcohol use categoriesAlcohol useVirologic responseCohort studyAntiviral therapyOdds ratioChronic hepatitis C virus (HCV) infectionAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionVeterans AffairsActing antiviral (DAA) therapyDAA treatment initiationHCV elimination goalsUndetectable HCV RNAC virus infectionFibrosis-4 scoreRetrospective cohort studyMultivariable logistic regressionTenth Revision diagnosisContingency management with stepped care for unhealthy alcohol use among individuals with HIV: Protocol for a randomized controlled trial
Edelman E, Dziura J, Deng Y, DePhilippis D, Fucito L, Ferguson T, Bedimo R, Brown S, Marconi V, Goetz M, Rodriguez-Barradas M, Simberkoff M, Molina P, Weintrob A, Maisto S, Paris M, Justice A, Bryant K, Fiellin D. Contingency management with stepped care for unhealthy alcohol use among individuals with HIV: Protocol for a randomized controlled trial. Contemporary Clinical Trials 2023, 131: 107242. PMID: 37230168, PMCID: PMC10460633, DOI: 10.1016/j.cct.2023.107242.Peer-Reviewed Original ResearchMeSH KeywordsAlcohol DrinkingCohort StudiesCOVID-19HIV InfectionsHumansPandemicsRandomized Controlled Trials as TopicConceptsUnhealthy alcohol useLong-term abstinenceAlcohol useContingency managementAlcohol consumptionFormal alcohol treatmentShort-term abstinenceMotivational enhancement therapyGOV IDENTIFIERSecondary outcomesWeek 24Primary outcomeWeek 12Preliminary efficacyTreatment trialsPhysician managementEfficacy trialsMedical conditionsAlcohol treatmentExploratory outcomesEnhancement therapyAbstinenceTrialsCareHealthy activities
2022
Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, Tetrault J, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Network Open 2022, 5: e2246604. PMID: 36515952, PMCID: PMC9856353, DOI: 10.1001/jamanetworkopen.2022.46604.Peer-Reviewed Original ResearchMeSH KeywordsAlcoholismAntiviral AgentsCohort StudiesHepacivirusHepatitis CHepatitis C, ChronicHumansMaleMiddle AgedConceptsCurrent alcohol use disorderLow-risk drinkingAlcohol use disorderVeterans Health AdministrationHistory of AUDDAA treatmentAlcohol use categoriesAUD historyCohort studyRisk drinkingUse disordersDirect acting antiviral (DAA) treatmentAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionHepatitis C virus (HCV) treatmentCox proportional hazards regressionC virus infectionC virus treatmentProportional hazards regressionTenth Revision diagnosisAUDIT-C questionnaireInternational Statistical ClassificationRelated Health ProblemsAntiviral treatmentRevision diagnosis
2016
Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. PMID: 27431048, PMCID: PMC4976086, DOI: 10.1016/j.jsat.2016.06.002.Peer-Reviewed Original ResearchConceptsLiver enzyme elevationAlcohol use disorderUninfected patientsHepatotoxic medicationsHCV infectionUse disordersComposite endpointLiver injuryHIV/HCV co-infected patientsHCV co-infected patientsHIV/HCV statusPre-existing liver injuryCo-infected patientsCohort of HIVHepatitis C infectionHIV/HCVOpioid use disorderRisk of hepatotoxicityHCV statusHepatic safetyMedian ALTC infectionChart reviewEnzyme elevationHIV infection
2011
Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone
Tetrault JM, Tate JP, McGinnis KA, Goulet JL, Sullivan LE, Bryant K, Justice AC, Fiellin DA, Team F. Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone. Alcohol Clinical And Experimental Research 2011, 36: 318-324. PMID: 21797892, PMCID: PMC3221963, DOI: 10.1111/j.1530-0277.2011.01601.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlanine TransaminaseAlcoholismAntiretroviral Therapy, Highly ActiveAspartate AminotransferasesCD4 Lymphocyte CountChemical and Drug Induced Liver InjuryCohort StudiesDatabases, FactualDrug InteractionsDrug-Related Side Effects and Adverse ReactionsFemaleHIV InfectionsHumansLiverLiver Function TestsMaleMiddle AgedNaltrexoneNarcotic AntagonistsOpioid-Related DisordersRNA, ViralVeteransConceptsNaltrexone prescriptionAlanine aminotransferaseOpioid dependenceVeterans Aging Cohort Study Virtual CohortAspartate aminotransferaseImpact of naltrexoneSignificant alanine aminotransferaseLiver enzyme elevationMean CD4 countHIV-infected individualsAST changesHepatic safetyHIV biomarkersOral naltrexoneCD4 countHIV RNAMedian durationEnzyme elevationMedian ageAST levelsNaltrexone useHepatic enzymesAntiretroviral effectivenessHIVPatients